Towa Pharmaceutical Co., Ltd.
Notice of Allotment of Shares in Tanabe Pharma Factory Co., Ltd. (Complete Subsidiary) and Succession of Manufacturing and Marketing Approval
Completely acquired Tanabe Pharma Factory Co., Ltd. as a subsidiary and inherited 17 components and 35 products in its manufacturing and marketing approvals. The acquired shares are 22,602 shares (100%), with transfer planned for late November 2026 and succession of approvals scheduled for April 2027 onward. Future production capacity aims to reach over 30 billion tablets in FY2036.
Key Figures
- Number of shares acquired: 22,602 shares (voting rights: 22,602)
- Acquisition price: Unknown
- Succession timing for manufacturing and marketing approvals: From April 2027 onward (17 components, 35 products)
AI要約
Section headline
The company will make Tanabe Pharma Factory a wholly owned subsidiary and succeed its manufacturing and marketing approvals to strengthen the domestic generic pharmaceutical supply security. Tanabe Pharma Factory possesses global-standard manufacturing and quality control systems; through the succession, product item consolidation and production efficiency improvements are targeted.
Section 2 headline
The share transfer will involve acquiring 22,602 shares (100%). The transfer is planned for late November 2026. The succession of manufacturing and marketing approvals is planned for April 2027 onward. Going forward, goodwill is expected to arise, and impacts will be disclosed as they are determined. The plan targets production capacity of 24 billion tablets in FY2030 and over 30 billion tablets in FY2036.
Toa Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
